iiinova — where your digital self keeps evolving

Reposted by Mark A Rubin

DBMR University Bern @dbmr-unibe.bsky.social · 01/07/2026

🎤 What are the insights that the movie #Jaws can be used to improve the grants one writes? 7 rules of grant writing with examples from movies and sports! @marubin1.bsky.social @medfacultyunibe.bsky.social

011

Reposted by Mark A Rubin

DBMR University Bern @dbmr-unibe.bsky.social · 23/06/2026

🔬 The #MSCA @mac4me.bsky.social network just wrapped its second consortium meeting & doctoral training! Five days of technical training, research collaboration, PPI, and professional communication. Great to see @marubin1.bsky.social & Marine Cullier contributing!

012

Reposted by Mark A Rubin

Journal of Experimental Medicine @jem.org · 28/05/2026

Researchers at Columbia University have identified a gene that drives the development of neuroendocrine prostate cancer, an aggressive form of the disease. 👉 www.eurekalert.org/news-release... See the original study by the Abate-Shen lab @columbiamed.bsky.social 👉 rupress.org/jem/article-...

021

Reposted by Mark A Rubin

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 10/02/2026

📣Updated ESMO #ClinicalPracticeGuideline on advanced and metastatic #ProstateCancer: ✅ Substantial advances in castration-sensitive & -resistant prostate cancer ✅ Updated algorithms & recommendations reflecting latest clinical data #ESMOGuidelines Christopher Sweeney 🔗 ow.ly/E4ov50Yc8e2

031

Mark A Rubin @marubin1.bsky.social · 07/02/2026

🧬 New preprint out! Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens. 🔗 doi.org/10.64898/202... #PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics

011

Reposted by Mark A Rubin

American Association for Cancer Research (AACR) @theaacr.bsky.social · 22/01/2026

Molecular Cancer Research editor Massimo Loda, Franklin W. Huang, Michael C. Haffner, and Irene Paassen discussed "Genomics and Epigenomics" in a plenary session at the AACR Special Conference on Innovations in Prostate Cancer Research and Treatment. #AACRprostate26 @aacrjournals.bsky.social

021

Mark A Rubin @marubin1.bsky.social · 20/01/2026

Can we help men with hormone-refractory #ProstateCancer through personalized epigenetic therapy? Our new study using patient-derived organoids reveals a targetable weakness in a WNT-driven subtype. @genentech.bsky.social @medfacultyunibe.bsky.social @unibe.ch @pmbern.bsky.social tinyurl.com/2tkn3hwh

032

Reposted by Mark A Rubin

DBMR University Bern @dbmr-unibe.bsky.social · 06/01/2026

New @natmed.nature.com News & Views by @marubin1.bsky.social and Dr. Irene Paassen on why #PrecisionOncology must go beyond genomics. @medfacultyunibe.bsky.social @pmbern.bsky.social tinyurl.com/2zvdvmy6

053

Reposted by Mark A Rubin

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 18/12/2025

📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer: ✅New imaging modalities: Improved diagnosis, staging & risk stratification ✅Updated algorithms: less over-Tx & fewer side-effects #Oncology #UroOncology #CancerCare #ESMOGuidelines 🔗 ow.ly/jwA650XLs1q

1123

Mark A Rubin @marubin1.bsky.social · 14/12/2025

Excited to share new preprint on the minor spliceosome in cancer! Targeting U6atac disrupts DNA repair and sensitizes prostate & breast tumors to radiation, cisplatin and PARP inhibitors—even beyond BRCA-mutant . bit.ly/48RnsI5 #DNARepair #ProstateCancer #BreastCancer #U6atac @theaacr.bsky.social

001